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DISSERTATION ABSTRACT 
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Dr. Eric Johnson 
 
 
Correct regulation of insulin/insulin-like growth factor signaling (IIS) is essential 
for proper development and growth. More recently, proper regulation of IIS has been 
shown to be important for adaptation and survival under stressful conditions. Despite the 
importance of IIS, the mechanism underlying IIS regulation under various environmental 
stresses remains to be elucidated.  One mechanism of regulating IIS involves the binding of 
insulin and insulin-like growth factors by insulin-like growth factor binding proteins 
(IGFBPs), which prevent the factors from interacting with the insulin receptor (InR). The 
only identified IGFBP in Drosophila to date is imaginal morphogenesis protein late 2 (Imp-
L2), which was previously implicated in the regulation of IIS during starvation. Here, we 
investigate whether Imp-L2 is required to regulate IIS under low oxygen stress (hypoxia).  
The ability to tolerate hypoxia requires cellular adaptations that decrease the need 
for oxygen and increase the supply of it. In a wide variety of organisms many of these 
adaptations are either directly or indirectly regulated by the transcription factor hypoxia-
inducible factor-1 (HIF-1). Our results reveal a regulatory link between HIF-1, Imp-L2, and 
IIS during hypoxia. We demonstrate that Imp-L2 transcript abundance is increased during 
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hypoxia in a HIF-1 dependent manner resulting in inhibition of IIS and increased hypoxia 
tolerance.  
 This dissertation includes unpublished co-authored material.  
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CHAPTER I 
 
INTRODUCTION TO INSULIN/INSULIN-LIKE GROWTH FACTOR 
SIGNALLING AND HYPOXIC GENE REGULATION 
 
Background to Insulin Signaling 
Insulin and insulin like growth factors (IGFs), along with their respective 
receptors and the insulin-like growth factor binding proteins (IGFBPs) all fall into the 
insulin superfamily of growth-promoting peptides and comprise the core components of 
the IGF system (1). Insulin/insulin-like growth factor signaling (IIS) is responsible for the 
regulation of cell survival, cell cycle kinetics, proliferation, body size, metabolism, 
fertility, and longevity in both vertebrates and invertebrates (2-4). IIS activity is regulated 
through both intracellular and extracellular signaling pathways, which includes the 
production and release of ligands and receptors, and through the binding activity of 
IGFBPs (2,3). It has been proposed that an ancient insulin-like gene with predominantly 
mitogenic properties was the common ancestor to insulin and IGFs I and II found in 
vertebrates as well as the insulin like peptides (ILPs) found in invertebrates as they all 
exhibit a high degree of homology (5).  
In vertebrates, the insulin receptor (IR), IGF-I receptor (IGF-IR) and IGF-II 
receptor (IGF-IIR) are preferentially but not exclusively bound by their respective ligands 
as IGF-II also binds the IR and the IGF-IR. Additionally, hybrid IGF/insulin receptors 
have been identified that increase the complexity of IGF system by varying the affinities 
of the receptors for the different ligands (6). Six IGFPBs have been identified in 
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vertebrates that bind the IGFs with high affinity and control their availability for receptor 
binding and as well as increase their half-lives in circulation and extracellular fluids. 
While insulin occurs in free form, the IGFs are all found in ternary complexes with 
IGFBPs and acid-labile subunit (ALS) in a 1:1:1 molar ratio (2,3,6). The binding of the 
IR or IGF-I by their respective ligands stimulates tyrosine-kinase pathways that initiate 
intracellular signaling cascades that are similar at their proximal ends. Divergence of the 
signaling pathways results in insulin primarily regulating metabolism and the IGFs 
primarily regulating mitogenic events. The IGF-IIR is though to primarily function in the 
removal of IGF-II from extracellular fluid (1,6).  
InR is the fruit fly (Drosophila melanogaster) homologue of the IR and IGF-IR in 
vertebrates with structural similarities to both (7). Additionally, seven insulin-like 
peptides have been identified in Drosophila (Dilp 1-7) that are homologous to vertebrate 
insulin and IGF-1; however, the first IGFBP homologue was only identified recently (8). 
Imaginal morphogenesis protein late 2 (Imp-L2) has been identified as an insulin-like 
growth factor binding protein (IGFBP) and putative homolog of vertebrate IGFBP-7 
(8,9). The superfamily of IGFBPs includes the six high-affinity IGFBPs and several low-
affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP), which 
includes IGFBP-7 (10). One aspect of IIS that is not well understood is the regulation of 
IGFBP expression and activity under varying conditions.  The discovery of an 
invertebrate IGFBP homologue provides the opportunity to further dissect IIS in a 
simpler model system. 
A better understanding of IIS is essential as malfunctions of this system are 
involved in many human diseases. In addition to the role of insulin in the metabolic 
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disorder diabetes mellitus, malfunction of the IGF system is strongly associated with a 
variety of human cancers. Increased transcription of one or more of the genes encoding 
IGF-I, IGF-II, IGF-IR and IR-A are observed in malignant tumors in various central 
nervous system cancers as well as prostate, breast, lung, colon, rectum, pancreas, liver 
and ovarian cancer.  On a broader scale, an increased risk of all-cause, cardiovascular and 
cancer mortality was observed in men with low IGF-I serum level concentrations and an 
increased risk of all-cause mortality was observed in men and women with low serum 
level concentrations of IGFBP-3 (1).  
 
Background to Hypoxia 
All eukaryotic organisms require molecular oxygen (O2) for cellular respiration. 
Aerobic respiration takes place in mitochondria where oxygen is the final electron 
acceptor during oxidative phosphorylation to generate adenosine triphosphate (ATP). In 
vertebrates, oxygen diffuses through alveoli in the lungs where is it delivered to 
hemoglobin for transport throughout the vascular system to the tissues where it is needed. 
Drosophila use a system of spiracles and trachea to deliver oxygen to tissues. Since 
oxygen is essential for the growth and survival of all obligate aerobes, low oxygen stress 
(hypoxia) is a key concern. A common observation is that hypoxia results in the 
suppression of somatic growth in humans at high altitude or with congenital heart disease 
or in infants with chronic lung disease. Similarly, Drosophila raised under hypoxia are 
smaller and take longer to develop (11).  
The ability to tolerate both acute and chronic hypoxia requires cellular adaptations 
that are mediated by hypoxia responsive transcription factors. In most, if not all, aerobic 
 4 
organisms, the master regulator of the hypoxic response is the transcription factor 
hypoxia-inducible factor-1 (HIF-1). HIF-1 is a heterodimeric protein consisting of an α-
subunit and a β-subunit. While both subunits are constitutively expressed, the α-subunit 
is rapidly degraded under normoxic conditions. When oxygen is scarce, the α-subunit 
accumulates in the cytoplasm, binds to the β-subunit to form active HIF-1, and 
translocates to the nucleus to regulate essential target genes (11-13). The transcriptional 
regulation of target genes allows cells to change their physiology in ways that allow them 
to better cope with hypoxia. 
 
Bridge to Chapter II 
In the previous chapter I described the fundamentals of insulin/IGF signaling in both 
vertebrates and invertebrates. Additionally, I described regulation of the transcriptional 
response to hypoxia. In Chapter II I report data form a paper currently under review for 
publication, of which I was the first author, which examined the function and regulation 
of an IGFBP during hypoxia in Drosophila melanogaster. The co-authors are Khoa D. 
Tran, Douglas W. Turnbull and Eric A. Johnson. 
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CHAPTER II 
 
DROSOPHILA INSULIN PATHWAY ACTIVITY IS REPRESSED DURING 
HYPOXIA BY IMPL2 IN A HIF-1 DEPENDENT MANNER 
 
Reproduced from J. Paul Allee, Khoa D. Tran, Douglas W. Turnbull, and Eric A. 
Johnson 
Submitted to Journal of Biological Chemistry May 6, 2011 
 
Khoa Tran contributed to this work by conducting antibody stains in embryos and 
larvae and by taking microscope images. Douglas Turnbull contributed by exposing wild-
type and HIF-1α homozygous mutant adult flies to hypoxia and isolating their RNA. I 
conducted the remainder of the experiments and was responsible for the experimental 
design as well as the data analysis and writing.  
Insulin/insulin-like growth factor signaling (IIS) is responsible for the regulation 
of cell survival, the cell cycle, proliferation, body size, metabolism, fertility, and 
longevity in both vertebrates and invertebrates (2-4). IIS activity is regulated through 
both intracellular and extracellular signaling pathways, which includes the production 
and release of ligands and receptors, and through the binding activity of insulin-like 
growth factor binding proteins (IGFBPs) (2,3). One aspect of IIS regulation that is not 
well understood is the control of IGFBP expression and activity under varying 
conditions. IGFBPs regulate the availability and activity of insulin-like growth factors 
(IGFs) by binding them with high affinity, thus preventing them from interacting with the 
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insulin receptor (InR) (2). Additionally, the formation of ternary complexes between 
IGFs, acid labile subunit (ALS) and IGFBPs prolongs the half-lives of IGFs and protects 
them from degradation (2,3). While seven insulin-like peptides have been identified in 
Drosophila (Dilp 1-7) that are homologous to vertebrate insulin and IGF-1, the first 
IGFBP homologue was only identified recently (8). Imaginal morphogenesis protein late 
2 (ImpL2) has been identified as an IGFBP and putative homolog of vertebrate IGFBP-7 
(8,9). This provides an opportunity to study regulation of IGFBP production and activity 
using the Drosophila model.  
ImpL2 was initially identified as one of six ecdysone inducible genes expressed 
during imaginal disc morphogenesis (14). Drosophila ImpL2 was later reported to be a 
secreted member of the immunoglobulin superfamily implicated in neural and ectodermal 
development based on patterns of mRNA expression (15). In 2000 a Drosophila ImpL2 
homologue was identified that could bind insulin and related peptides in the insect 
Spodoptera frugiperda, and later Drosophila ImpL2 was shown to bind to and antagonize 
Drosophila insulin like peptide 2 (Dilp2) and inhibit IIS (8,16,17).  Although ImpL2 is 
not essential in standard conditions, homozygous mutants are larger than wild-type. 
During adverse nutritional conditions ImpL2 expression increases in the fat body, and 
homozygous mutants have much higher mortality rates (8). These results provide a strong 
argument that ImpL2 is an IGFBP that not only plays a role in regulating growth during 
development, but also is also required for regulating the activity of IIS during starvation. 
The ability to tolerate hypoxia requires cellular adaptations that decrease the need 
for oxygen and increase the supply of it. In a wide variety of organisms, many of these 
adaptations are either directly or indirectly regulated by the transcription factor Hypoxia-
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inducible factor-1 (HIF-1) (12,13). HIF-1 is a heterodimer consisting of a bHLH-PAS α-
subunit and a β-subunit that is a common partner to several other bHLH-PAS proteins. 
The HIF-1α and HIF-1β subunits are constitutively expressed under normoxia but the α-
subunit is rapidly degraded under normoxic conditions via oxygen dependent 
hydroxylation by proline hydroxylases, followed by recognition and polyubiquitination 
by pVHL, and subsequent proteolysis. Under hypoxic conditions the α-subunit is 
stabilized, allowing it to bind to the β-subunit and form active HIF-1, which is then able 
to bind specific DNA enhancer sequences, known as hypoxia response elements (HREs), 
and regulate target gene activity (13,18-20).  
Two hallmarks of the response to hypoxia are likely due to an attempt to conserve 
energy: small flies and slower developing flies, which we examine in this study. Flies 
reared under varying levels of hypoxia, or stressed with hypoxia at any developmental 
stage, are smaller than wild-type as available oxygen provides a physical constraint on 
insect body size (11,21-24). Hypoxia also negatively affects cell cycle kinetics resulting 
in a lengthening of the cell cycle, which slows development (25,26). Additionally, Severe 
hypoxia (< 3%) directly limits ATP production resulting in lowered rates of protein 
synthesis, feeding, digestion and absorption (11). Here we investigate the possible link 
between oxygen starvation, ImpL2 expression, and insulin signaling. ImpL2 transcript 
abundance was previously reported to be elevated during hypoxia by microarray studies 
of Drosophila gene expression (27). Our results confirm the previously reported increase 
in ImpL2 during hypoxia and demonstrate that this upregulation is HIF-1 dependent. 
Additionally, we show that the ImpL2 transcripts are being actively translated during 
hypoxia. We find that ImpL2 is required for hypoxic tolerance in adult flies and that it 
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affects the rate of development in a dosage dependent manner. Coupled with these 
findings we also show that IIS is repressed under hypoxia and that this repression 
requires both functional HIF-1 and ImpL2. Thus, hypoxia-induced ImpL2 expression is 
dependent on HIF-1 and inhibits IIS and promotes hypoxia tolerance.  
 
EXPERIMENTAL PROCEDURES 
  Fly stocksThe following pre-existing fly stocks from Bloomington Stock 
Center were used: Oregon-R, Canton S, sima7607, tGPH, UAS-simaB, Lk6-GAL4 for 
expression in larval fat body, Elav-GAL4 for expression in embryos and en-GAL4. 
  The laboratory of Ernst Hafen provided the following stocks that were used in this 
study: UAS-s.ImpL2 and ImpL2Def42/TM3, Sb, which was denoted as ImpL2+/- in this 
study (8). Flies listed as ImpL2-/- were ImpL2Def42/ImpL2Def42. 
Tissue preparation and immunohistochemistryStage 16 embryos were 
dechorionated and fixed in the standard fashion and antibody staining was performed as 
described previously (28). In short, embryos were fixed for 20 minutes at 23°C in 4% 
formaldehyde, blocked for 20 minutes with 5% normal goat serum, and incubated with 
primary antibodies at 4°C overnight. Secondary antibody incubations were performed at 
23°C for 2 hours.  Embryos where mounted in glycerol and imaged on confocal 
microscopes.  Feeding 3rd instar larvae were dissected in PBS to expose fat body and then 
antibody staining was performed as described previously (8).  
Molecular MarkersThe rat anti-ImpL2 was previously described (15) and 
provided by J. Natzle (Department of Molecular and Cellular Biology, University of 
California, Davis, USA). Chicken anti-rat HRP 1:5000 (Santa Cruz Biotechnology), 
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mouse anti-GFP 1:500 (Molecular Probes), chicken anti-GFP 1:500 (Aves Laboratories, 
Inc.) and Alexa Fluor® 646 phalloidin 1:200 (Molecular Probes). Secondary antibodies 
were Alexa Fluor® 488 goat anti-mouse 1:500 (Molecular Probes) and Alexa Fluor® 488 
goat anti-chicken 1:500 (Molecular Probes) were also used in this study.  
  Relative qPCRTotal RNA was isolated using standard TRIzol protocols. cDNA 
was synthesized following the Super-Script III Reverse Transcriptase protocol 
(Invitrogen). Real-time PCR was performed using the Sybr Green PCR Master Mix 
(Applied Biosystems) and a StepOnePlus Real-Time PCR system (Applied Biosystems). 
Baseline and efficiency were calculated using LinRegPCR software (29). ΔΔCt values 
were calculated using StepOnePlus software (Applied Biosystems). The following 
primers were used: ImpL2 (5'-TTCGCGGTTTCTGGGCACCC-3' and 5'-
GCGCGTCCGATCGTCGCATA-3'), Actin5c (5′-GGATGGTCTTGATTCTGCTGG-3' 
and 5′-AGGTGGTTCCGCTCTTTTC-3') and Rp49 (5'-
ATGACCATCCGCCCAGCATAC-3' and 5'-GAGAACGCAGGCGACCGTTGG-3'). 
MicroscopyConfocal image stacks were collected using a Leica SP2 or Bio-Rad 
Radiance 2000 confocal microscope and displayed as two-dimensional projections. 
Confocal images were processed using ImageJ, Adobe Photoshop CS3 and Adobe 
Illustrator CS3.  
 
RESULTS 
ImpL2 transcript abundance is increased during hypoxia in a HIF-1 dependent 
mannerMicroarray analysis previously revealed a more than four-fold increase in 
ImpL2 transcript abundance in adult flies in response to 6 hours of hypoxic stress at 0.5% 
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O2. By comparing transcript abundance in response to hypoxia for both wild-type and 
HIF-1α homozygous mutant adult flies using relative qPCR, we verified the previous 
result and determined that HIF-1 is required for the induction of ImpL2. While a four-fold 
increase is seen between normoxic and hypoxic wild-type adults, no significant 
difference is seen in HIF-1α homozygous mutants (Fig. 1). Therefore, HIF-1 is required 
for the increase in ImpL2 in response to hypoxia.  
ImpL2 protein is elevated under hypoxic stressOne response to hypoxia is 
reduced translational activity.  Thus, we examined ImpL2 protein levels during hypoxia 
to determine if the increased transcript abundance was correlated with increased protein 
levels. First, we confirmed that we could detect ImpL2 protein specifically by examining 
ImpL2 over-expression embryos (Elav-GAL4;UAS-s.ImpL2) compared to wild-type 
embryos.  We used Elav-GAL4 as a previously characterized pan-neuronal driver with 
strong expression in embryos (30).  Using a previously generated antibody against ImpL2 
(8), we found a clear and observable increase in detectable ImpL2 protein in Elav-
GAL4;UAS-s.ImpL2 embryos (Fig. 2A). Next, we examined and observed an increase in 
the level of ImpL2 protein in response to hypoxia (Fig. 2B). Interestingly, hypoxia 
consistently resulted in a greater increase in ImpL2 protein levels than pan-neuronal over-
expression, suggesting that a greater number and variety of cells were producing ImpL2 
protein.  Because most translation is shut down under hypoxia (31), the active translation 
of ImpL2 suggests that ImpL2 is performing an essential function during hypoxic stress.  
Increased HIF-1 expression is sufficient for increased ImpL2 protein levelsTo 
test whether HIF-1α is sufficient to induce ImpL2 expression; we examined ImpL2 
protein levels in HIF-1α over-expression embryos.  Immunohistochemistry in stage 16 
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embryos revealed that over-expression of HIF-1α (Elav-GAL4;UAS-simaB) results in an 
increase in ImpL2 protein levels (Fig. 2C). Over-expression of HIF-1α is sufficient to 
induce ImpL2 expression in the absence of any environmental stress. Although HIF-1α is 
rapidly degraded under normoxia, over-expression is presumably able to override the rate 
of degradation allowing for HIF-1α to dimerize with HIF-1β and translocate to the 
nucleus for the activation of target genes. Coupled with the qPCR data, we conclude that 
HIF-1 is both necessary for the increase in ImpL2 during hypoxia and sufficient to 
promote its expression during normal conditions.  
ImpL2 is required for hypoxic toleranceWhile wild-type flies are very tolerant 
of moderate hypoxia (10% O2) and can develop fully under these conditions, ImpL2-/- 
flies raised under the same conditions fail to eclose and many die prior to pupariation 
(data not shown). Using a survival assay of stressing adult flies with 1.3+/-0.1% for 24 
hours, we found that the survival rates of male wild-type, ImpL2+/-, ImpL2-/- and HIF-1α-/- 
were approximately 75%, 62%, 46% and 42% respectively (Fig. 3). The differences in 
survival were all statistically significant except when comparing ImpL2-/- and HIF-1α-/- 
flies, which showed no significant difference. Even the loss of one copy of ImpL2 
impaired the survival of flies stressed with hypoxia, suggesting that proper levels of 
ImpL2 are needed for an optimal response to hypoxic stress. 
IIS is repressed during hypoxiaTo investigate whether IIS is affected during 
hypoxia we used tGPH flies to assay insulin signaling activity (8). Transgenic tGPH flies 
express a pleckstrin homology domain: GFP fusion protein, which binds to PIP3 to 
visualize IIS activity. When insulin binds the insulin receptor, PI3K phosphorylates PIP2 
to PIP3 at the cell cortex. Therefore, when insulin signaling is active, PIP3 accumulates at 
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the cortex and GFP becomes cortically enriched. In contrast, when insulin signaling is 
inactive, GFP becomes cytoplasmically diffuse.  Thus, immunostaining against GFP 
allows for visualization of IIS signaling based on cortical localization. We observed that 
IIS is clearly repressed in the fat body of feeding 3rd instar larvae stressed with 0.5% O2 
for as little as one hour (Fig. 4).  
ImpL2 is both necessary and sufficient for the repression of IIS during 
hypoxiaExamining the location of GFP in the fat body of feeding 3rd instar larvae 
carrying the tGPH reporter we observed that IIS remains active in ImpL2 homozygous 
mutants during hypoxia (Fig. 4). Over-expression of ImpL2 in the fat body of normoxic, 
feeding 3rd instar larvae using Lk6-GAL4;UAS-s.ImpL2 flies resulted in silencing of IIS 
(Fig. 4). Additionally, over-expression of HIF-1α results in IIS silencing (Fig. 4). Thus, 
both HIF-1 and ImpL2 expression is sufficient to reduce IIS, and ImpL2 is required for 
the reduction in IIS during hypoxia. 
ImpL2 dosage affects rate of developmentThe average time to develop from 
embryo to eclosion is 13 days for normoxic wild-type flies and 17 days for hypoxic wild-
type flies at 22°C (Fig.5). ImpL2-/- flies develop in 11 days and flies over-expressing 
ImpL2 or HIF-1α require 17-18 days to develop (Fig. 5). Flies unable to inhibit insulin 
signaling during development could be expected to develop faster while those that 
experience increased repression of IIS would likely develop slower. This is consistent 
with the published finding that ImpL2 mutants are larger than wild-type flies when 
weights are taken after feeding for 3 days from eclosion.    
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DISCUSSION 
Hypoxia is a severe environmental stress that brings about a host of changes at the 
organismal, cellular and molecular levels. A key regulator of many of these changes is 
HIF-1, which alters the transcription of target genes during hypoxia. We have previously 
shown that targets of HIF-1 regulation extends to controlling the activities of other 
signaling pathways such as the heat shock response, and thus is able to tune a wide range 
of cellular activities (32).  Here we demonstrate that HIF-1 is required and sufficient for 
regulating IIS during hypoxia through the increased expression of the IGFBP ImpL2, and 
that this regulation is a critical aspect of hypoxia tolerance.  Thus, these data link together 
two important pathways that respond to the environment, and show that their coordinated 
action is needed for an optimal response to low oxygen. 
Our results do not support an indirect model of IIS regulation by hypoxia.  That 
is, the increase in ImpL2 and reduction in IIS seen in response to hypoxia could be the 
result of starvation given that IIS is reduced following nutrient deprivation and adult flies 
or larvae stressed with severe hypoxia enter a hypoxic stupor and cease feeding (27). 
However, one hour of severe hypoxia (<1.5% O2) is sufficient for the complete 
repression of IIS in larval fat body (Fig. 4) while 4 hours of starvation is required for a 
similar but less significant effect (8). Second, over-expression of HIF-1 or ImpL2 with 
the Lk6-GAL4 driver clearly reduces IIS in the larval fat body during normoxia (Fig. 4) 
but does not lead to cessation of feeding or development and is therefore comparable to 
mild hypoxia (Fig. 5) (11). Third, chronic mild hypoxia (5-7% O2) prolongs development 
independent of nutritional state as flies continue to feed and grow under these conditions. 
Fourth, HIF-1 is required for the hypoxic induction of ImpL2 in adults, and sufficient for 
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the induction of ImpL2 in normoxic embryos (Fig. 1, 2). Furthermore, HIF-1 is sufficient 
for the reduction of IIS observed in feeding normoxic third instar larvae (Fig 4). We 
conclude that the increase in ImpL2 and associated silencing of IIS observed during 
hypoxia is not a result of starvation but a direct result of HIF-1 activity. 
While hypoxia and IIS both affect many components of growth and survival and 
share common target genes, hypoxia has not been previously reported to directly repress 
IIS (33). We propose a model wherein HIF-1 activation during hypoxia promotes the 
expression of ImpL2, which acts as an IGFBP and suppresses IIS resulting in slowed 
development, smaller flies, and hypoxia tolerance. In support of this model we 
demonstrated that ImpL2 levels increase in response to hypoxia in a HIF-1 dependent 
manner, that ImpL2 is required for hypoxia tolerance in a dose dependent manner, that 
ImpL2 dosage affects development rates, and that hypoxia represses IIS in an ImpL2 
dependent manner. Additionally, IIS is known to be silenced during the wandering stage 
at the end of the 3rd instar as larvae prepare for pupariation; however, IIS remains active 
during this stage in ImpL2 homozygous mutants (data not shown). This observation that 
ImpL2 is required for normal silencing of IIS during wandering as well as in response to 
environmental stresses implies that ImpL2 is required for proper regulation of IIS during 
all life stages and is responsible for the developmental delay we observed. 
Our data support the conclusion that ImpL2 functions as an IGFBP in order to 
modulate IIS activity both during normal development and during any time of 
environmental stress from embryo development through adulthood. Our results also 
suggest that ImpL2, a putative homolog of vertebrate IGFBP-7, may be the only 
functional IGFBP in Drosophila as flies are unable to compensate for its loss. The lack of 
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redundancy in this instance is tolerable because ImpL2 is dispensable under normal 
conditions with homozygous mutants exhibiting only minor changes in size and 
developmental rate. Our results further the understanding of the critical role ImpL2 plays 
in silencing IIS during times of environmental stress to promote survival, and 
demonstrate the broad role HIF-1 has in orchestrating the activity of multiple cellular 
pathways in response to stress. 
 
BRIDGE TO CHAPTER III 
 In the previous chapter I reported data form a paper currently under review for 
publication, of which I was the first author, which examined the function and regulation 
of the IGFBP ImpL2 during hypoxia in Drosophila melanogaster. We demonstrated that 
hypoxia-induced ImpL2 expression is dependent on HIF-1, inhibits IIS and promotes 
hypoxia tolerance. In chapter III I report on my research findings into the regulation and 
function of another hypoxia-response gene, the bHLH transcription factor hairy. 
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CHAPTER III 
 
THE REGULATION AND FUNCTION OF THE HYPOXIA-RESPONSE GENE 
HAIRY IN ADULT DROSOPHILA 
 
Drosophila hairy is a member of the Hairy and Enhancer of split (HES) gene 
family encoding a basic-helix-loop-helix (bHLH) transcription factor that is well 
characterized for its role as a primary pair-rule gene and negative regulator of fushi 
tarazu (ftz) during embryogenesis (34‐37). Transcription factors are a class of DNA 
binding proteins that regulate gene expression. Additionally, hairy is a repressor of 
achaete and scute during peripheral nervous system development in larvae and pupae. 
Hairy is required for the proper patterning of sensory bristles and derives its name from 
the mutant phenotype (38-42).  
The bHLH transcription factors are a well-conserved yet functionally diverse 
class of regulatory proteins found in animals, fungi and plants. Much less is known about 
plant bHLH proteins compared to those found in other eukaryotes (43-46). Different 
subfamilies of bHLH proteins function as dedicated activators, dedicated repressors or a 
combination of the two. The primary function of one subclass of bHLH proteins found in 
both invertebrates and vertebrates, known as Class C bHLH proteins, is the repression of 
target genes through the recruitment of other non-DNA binding proteins (41,47). The 
HES family of proteins in Drosophila is composed entirely of Class C bHLH proteins. 
HES proteins contain a basic domain for DNA binding, a Helix-Loop-Helix domain for 
dimerization, an Orange domain for specificity, and a WRPW motif for binding the 
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potent co-repressor Groucho. Additionally, hairy contains a domain anterior to the 
WRPW motif that binds Drosophila C-terminal Binding Protein (dCtBP), another co-
repressor (Fig. 6) (48‐51). HES proteins are required throughout development as 
transcriptional repressors of genes necessary for a variety of processes including 
segmentation, neurogenesis and sex determination. Groucho is an essential co-repressor 
in vertebrates and invertebrates that is known to bind hairy and enhance target gene 
repression (41,52-58). Hairy has been well characterized as a dedicated transcriptional 
repressor in all biological processes it is known to be involved in (59-67).  
 Hairy was identified by microarray analysis as increasing in transcript abundance 
in adult Drosophila in response to hypoxia, which was subsequently confirmed by semi-
quantitative RT-PCR. It was reported that hairy is necessary for recovery from hypoxic 
paralysis and survival under prolonged hypoxia (27). Both the increase in transcript 
abundance and requirement for hypoxic tolerance supported a previously uncharacterized 
role for hairy in helping adult flies to adapt to and survive hypoxia. With no previous 
reports of hairy activity outside of embryo and larval development, we were interested in 
how hairy was being regulated during hypoxia in adults, whether or nor it was acting as a 
transcriptional repressor, and what genes it was regulating. Here I describe my findings 
regarding the regulation and function of hairy during hypoxia. 
 
EXPERIMENTAL PROCEDURES 
 Fly Stocks The following pre-existing fly stocks were obtained from 
Bloomington Stock Center: Oregon R, h1, h25, and h41.  In order to minimize differences 
in gene expression due to variations in the genetic backgrounds of the strains that were 
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studied, both the wild-type Oregon R control strain and each mutant were crossed to the 
mapping stock: yw;Sp/CyO;Dr/TM3Sb.  The genotype of the wild type control strains 
were yw;Sp/CyO;+/+ and yw;Sp/CyO;+/TM3Sb.  The genotypes of the mutant strains 
studied were as follows: yw;Sp/CyO;h1/h1, yw;Sp/CyO;h25/TM3Sb, and 
yw;Sp/CyO;h41/TM3Sb. 
Adult Hypoxia Treatment15 male and 15 female adult flies form each genotype 
between the ages of 3 to 7 days post-eclosion were anaesthetized with CO2 and placed in 
separate vials containing standard Drosophila medium for each hypoxia experiment. 
After a 24-hour recovery period vials of the wild type strain and each mutant were placed 
in a sealed chamber at 22°C that was then flushed with a mixture of 0.5% O2 and 99.5% 
N2 (severe hypoxia). The other vials for each respective genotype were placed in an 
identical chamber at 22°C containing normal atmospheric oxygen concentrations.  The 
flies were incubated under either hypoxia or normoxia for six hours. Following the 
treatment, the flies were removed quickly and immediately frozen in liquid nitrogen.  
 RNA Extraction and Microarray ExperimentsFollowing either hypoxia or 
normoxia treatment, frozen flies were homogenized in TRIzol reagent and RNA was 
extracted according to the manufacturer’s protocol (Invitrogen).  For each strain, 20 µg of 
RNA from each normoxia and hypoxia treatment were labeled for microarray 
hybridization using the SuperScript Direct cDNA Labeling System (Invitrogen), 
incorporating either Cyanine 3 or Cyanine 5 conjugated dUTP (Perkin Elmer).  In each 
strain, gene expression during hypoxia was assayed by combining labeled normoxia and 
hypoxia cDNA, and hybridizing the samples to DNA microarrays containing 16,416 
oligonucleotides from the INDAC set representing the D. melanogaster transcriptome 
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(Illumina). Microarrays were scanned and analyzed using Gene Pix Pro 6.0 software 
(Molecular Devices). We then examined the expression level of transcripts in wild-type 
flies compared to the hairy mutant strains in order to identify genes that were 
differentially regulated during hypoxia in order to identity possible hairy targets.  
Cell Culture and Hypoxia TreatmentsDrosophila melanogaster Kc167 and S2 
tissue culture cells were obtained from the Drosophila Genomics Resource Center 
(DGRC). Cells were maintained in Schneider’s Drosophila medium (Invitrogen) 
supplemented with 5% (for Kc167 cells) or 10% (for S2 cells) heat-inactivated fetal bovine 
serum (Invitrogen). For hypoxia experiments, cells were incubated for 6 hours at 22°C in 
chambers flushed with 0.5% O2 and 99.5% N2. Following the treatment, total RNA was 
isolated using standard TRIzol protocols. The synthesis of cDNA and microarray 
experiments were perfomed as described above.  
 RNA Interference (RNAi)RNAi was performed as previously described (68). 
The following primer pairs were used to generate template DNA: control green 
fluorescent protein (GFP) (5’-GCCACAAGTTCAGCGTGTCC-3’ AND 5’-
GCTTCTCGTTGGGGTCTTTC-3’), hairy (5’-CCGACTGTGTGAACGAGGTTAGC-3’ 
and 5’-TGACCGATGGCTTGATGTCC-3’). The T7 promoter sequence (5’-
TAATACGACTCACTATAGGGAGA-3’) was added to the 5’ end of all the above 
primers when ordered (IDT).  
 Hypoxia Reporter ConstructionA small region of the hairy gene containing 
putative HREs was cloned into into the p-Green H Pelican reporter vector. Kc167 cells 
were then transfected with the recombinant reporter plasmid using the Effectene® 
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Transfection Reagent Kit (Qiagen) and then either left under normoxia or placed under 
hypoxia as described above.  
 
RESULTS 
 The hairy gene region contains conserved putative HREsWe used a 
bioinformatic approach to search for putative HIF-1 binding sites in the hairy gene 
region. Since HIF-1 is the master regulator of the hypoxic response it is the prime 
candidate for regulation of any hypoxia-response gene. Additionally, we have repeatedly 
observed an increase in hairy transcript in response to hypoxia in both adults and 
Drosophila Kc cells, and this increase appears to be HIF-1 dependent as HIF-1α RNAi in 
Kc cells reduces the increase in hypoxia induced hairy transcription and a similar result is 
seen in HIF-1α mutant flies (Unpublished data). Hairy contains multiple putative HREs 
that are conserved in the genomes of several Drosophila species (Fig. 7). 
 The putative HREs near hairy are not bound by HIF-1 during hypoxiaWe next 
tested whether the HREs had a regulatory function during hypoixa. Having identified a 
cluster of conserved putative HREs upstream of hairy we cloned them upstream of a 
minimal promoter driving GFP in the p-Green H Pelican reporter vector (69). We then 
co-transfected Kc cells with this reporter vector and a puromycin resistance vector. After 
selecting for stable transfectants we placed the cells under normoxic or hypoxic 
conditions. If the HREs were functionally relevant then the hypoxic cells would have 
shown a dramatic increase in GFP fluorescence compared with normoxic cells. The 
hypoxic cells transfected with the reporter vector did not show an increase in GFP 
fluorescence, suggesting they are not functionally relevant, and therefore, not bound by 
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HIF-1. As a control, Kc cells were transfected with a reporter vector containing a portion 
of the second intron of heat shock factor (Hsf) which is know to include functionally 
relevant HREs (32). The hypoxic cells containing this reporter showed a dramatic 
increase in GFP fluorescence compared to normoxic cells.  
 The transcriptional response of hairy mutants to hypoxia is the same as in wild-
type fliesDNA microarrays were used to compare the transcriptional responses of both 
wild-type and hairy mutant adult Drosophila melanogaster that had been stressed with 
hypoxia with those who had remained under normoxic conditions. Only transcripts 
exhibiting a fold change of 0.59 or greater on the log2 scale were considered. On a log2 
scale, 0.59 (20.59) is equivalent to a 2-fold change in transcript abundance so only genes 
with at least a 2-fold increase were evaluated in this study. After exposure to hypoxic 
stress, wild-type flies exhibited a 2-fold or greater increase in 164 transcripts while hairy 
mutants exhibited an increase in 208 transcripts. Although more genes increased in 
transcript abundance from exposure to hypoxia in hairy mutants than in wild-type flies, 
the overall transcriptional responses were surprisingly similar (Table 1).  
 Since hairy is considered a dedicated transcriptional repressor, we expected to see 
a significant increase in transcript abundance in a subset of genes in the hairy mutants 
with the reasoning being that they were no longer under repression. On the contrary, 
microarrays with hairy mutants produced results surprisingly similar to controls. We were 
limited to working with either heterozygous amorphs (h25 and h41) or a homozygous 
hypomorph (h1), as hairy null alleles are homozygous lethal. After performing microarray 
experiments with both classes of mutants we concluded that perhaps there was not a 
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sufficient reduction in hairy protein to see a clear effect on target genes so we decided to 
try RNAi in Drosophila Kc cells.  
RNAi based silencing of hairy in Kc cells results in no significant transcriptional 
changes during hypoxia compared to controls DNA microarrays were used to compare 
the transcriptional responses of control Kc cells and Kc cells treated with hairy-RNAi 
that had been stressed with hypoxia with those who had remained under normoxic 
conditions. We confirmed knock-down (KD) of hairy transcript abundance in cells 
treated with hairy-RNAi with semi-quantitative RT-PCR. Although the actual number of 
genes that changed in transcript abundance varied between controls and hairy-KD cells, 
the overall transcriptional responses were very similar for important genes of known 
function (Table 2). Only the top 200 transcripts are displayed for each group of cells. 
Microarray experiments did not result in the identification of any clear candidate genes as 
Hairy targets during hypoxia. 
 Putative Hairy targets previously identified by DamID increase in transcript 
abundance during hypoxiaA previously published paper reported the use of a 
chromatin profiling technique known as DamID to identify direct targets of Hairy (42). In 
this technique an E. coli adenine methyltransferase (DAM) tethered to a chromatin 
binding protein leads to specific methylation of DNA adjacent to the protein binding sites 
(70-72). When we compared the findings from the DamID experiments to our microarray 
results we identified six genes that were differentially expressed during hypoxia that were 
also identified as putative direct targets of Hairy: kayak, ImpL2, astray, Smg5, CG13868 
and CG15745. Additionally, all six genes contain conserved Hairy binding sites with the 
motif CACGCG. Surprisingly, all five genes increase in transcript abundance during 
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hypoxia, which would not be expected of the direct targets of a dedicated transcriptional 
repressor; on the contrary, we would expect to see those genes downregulated. There is 
no significant change in the hypoxic response for four of the six aforementioned genes in 
hairy mutants. The two genes that are expressed differently in hairy mutants (Smg5 and 
CG15745) actually show diminished transcriptional upregulation in response to hypoxia.  
  
DISCUSSION 
A better understanding of the regulation and function of the Drosophila gene 
hairy is important because of the critical role the mammalian homologues (HES1-6) play 
during many stages of human development and in tumorogenesis. HES1 is the primary 
mammalian homologue of hairy but all of the HES genes share a common structure and 
function as transcriptional repressors that are crucial components in the regulation of 
many biological processes including neurogenesis, eye development, somite 
segmentation, neural stem cell maintenance, embryonic stem cell differentiation, adult 
and pediatric tumor metastasis, and glia lineage restriction of neural progenitors in the 
injured or diseased central nervous system (73-81). This study proposes a novel role for 
hairy in promoting hypoxia tolerance in adult Drosophila melanogaster and identifies six 
putative hypoxia-response targets, one of them being the IGFBP ImpL2 described in 
Chapter II.  
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BRIDGE TO CHAPTER IV   In the previous chapter I provided background on the function of bHLH proteins as a class of transcription factors found in all metazoa. Additionally, I described the results of my investigations into the regulation and function of the hypoxia‐response gene hairy, a homologue of the mammalian HES1 gene. In Chapter 
IV I will summarize the findings from Chapters II and III and highlight the broader 
significance of these results.   
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CHAPTER IV 
 
CONCLUSION 
 Insulin/Insulin‐Like growth factor signaling (IIS) plays a critical role in regulating many aspects of normal development including, but not limited to, proliferation, body size, metabolism, fertility, and longevity. Mis-regulation of IIS is 
associated with diabetes miletus, numerous human cancers and an increased risk of all-
cause death in men and women alike. A better understanding of the molecular 
mechanisms underlying IIS is imperative for advancements in the treatment of various 
developmental disorders and diseases. Drosophila melanogaster has proved to be an 
invaluable model organism for unraveling many biological mysteries related to human 
development and disease with discoveries in flies very often being applicable to humans. 
Approximately 50% of Drosophila protein sequences have human homologues and 75% 
of human disease genes have Drosophila counterparts or homologues.  
In chapter II I reported on significant findings I made that elucidated both the 
regulation and function of the hypoxia-response gene ImpL2. Using relative qPCR I 
confirmed that the transcriptional increase of ImpL2 during hypoxia that was previously 
observed in microarrays and demonstrated that the increase in ImpL2 transcript 
abundance was dependent upon HIF-1. Using antibodies to ImpL2 in embryos I 
determined that the ImpL2 transcripts were being translated during hypoxia and that HIF-
1 over-expression was sufficient to promote an increase in ImpL2 protein levels during 
normoxia thus supporting a regulatory role for HIF-1. By comparing survival rates of 
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wild-type and ImpL2 mutants to hypoxic stress I demonstrated that ImpL2 was required 
for hypoxia tolerance in adult flies. Using transgenic tGPH flies I was able to determine 
that IIS is repressed in the fat body of feeding 3rd instar larvae during hypoxic stress and 
that ImpL2 was both necessary and sufficient for the repression of IIS during hypoxia. 
Finally, by comparing the developmental rates of wild-type, ImpL2 mutant, and ImpL2 
over-expression flies I observe that ImpL2 dosage affects the rate of development. My 
finding supported my initial hypothesis that activation of HIF-1 during hypoxia promotes 
the expression of ImpL2, which in turn functions as an IGFBP to inhibit IIS and promote 
hypoxia tolerance. 
In chapter III I reported on the results of my investigation into the regulation and 
function of another hypoxia-response gene, hairy. While hairy proved to be more 
enigmatic than ImpL2, I was able to show that while there are multiple putative HREs in 
the hairy gene region, they do not appear to be directly bound by HIF-1 during hypoxia. 
Additionally, using microarrays to assay the entire Drosophila transcriptome during 
normoxia and hypoxia, I demonstrated that anything short of a complete loss of gene 
product was insufficient to alter the transcriptional response of adult flies or cells in 
culture. And finally, I was able to identify six putative direct targets of Hairy that 
changed in transcript abundance during hypoxia. This was puzzling, however, since 
Hairy is considered a dedicated transcriptional repressor while my findings suggest it 
may be acting as a transcriptional activator. Of particular interest was the finding that 
Hairy is implicated in the regulation of ImpL2.  
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APPENDIX A  
FIGURES WITH LEGENDS FOR CHAPTER II 
 
 
 
Fig. 1. ImpL2 transcription is elevated during hypoxia in a HIF-1 dependent manner. 
Quantification of ImpL2 transcript levels by relative qPCR both confirms the increase in 
transcript abundance previously reported by microarray and reveals that HIF-1α is 
required for the increase in ImpL2 transcript during hypoxia. While there is significantly 
more ImpL2 in hypoxic wild-type flies than in normoxic flies, there is no significant 
difference in ImpL2 levels between normoxic and hypoxic HIF-1α homozygous mutants. 
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Fig. 2. ImpL2 protein is elevated during hypoxia. A. Antibody detection in wild-type 
embryos confirms a detectable increase in ImpL2 protein levels when over-expressed 
with a pan-neuronal GAL4 driver. ImpL2 is labeled in green and the EVE+ U1-U5 
motorneurons are labeled in red as a control for imaging depth. B. A considerable 
increase in ImpL2 protein levels is also observed during hypoxia. C. Over-expression of 
sima (Drosophila HIF-1α) using the same pan-neuronal driver as before results in an 
increase in ImpL2 protein levels in normoxic embryos. All panels show two segments of 
a stage 16 embryo.  Panels are presented as Z-projections covering the U1-U5 
motorneurons (~ 20 um).  N > 20 for all experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. ImpL2 is required for hypoxic tolerance in adult flies. Flies missing one copy of 
ImpL2 are more sensitive to hypoxia. Additionally, flies missing both copies have a 
survival rate no different than HIF-1α homozygous mutants. Reductions in survival 
between ImpL2+/-, ImpL2-/-, and wild-type are statistically significant. * All p-values are 
0.005 or less. Error bars represent standard error of the mean. Results shown are from 
four biological replicates. 
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Fig. 4. ImpL2 is necessary for the repression of IIS during hypoxia in larval fat body. 
Phalloidin staining is shown in the left column to reveal the cell membrane. tGPH 
fluorescence, a reporter for IIS activity, is shown in the right column under varying 
conditions. A. Cortical enrichment of tGPH in wild-type feeding third instar larvae 
indicates normal IIS activity. IIS activity is repressed during hypoxia as evidenced by the 
loss of cortical localization of tGPH. B. tGPH expression in ImpL2 homozygous mutants 
during hypoxia is similar to expression in wild-type normoxic larvae, indicating active 
IIS. C, D. IIS activity is repressed during normoxia when either ImpL2 or sima 
(Drosophila HIF-1α) is over-expressed in the larval fat body using the Lk6-Gal4 driver. 
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Fig. 5. ImpL2 dosage affects rate of development. Wild-type flies reared at 22°C eclose 
after approximately 13 days after egg laying. In contrast, ImpL2-/- flies develop 2 days 
faster, while over-expression of ImpL2 slows development by 4 days. In a similar 
manner, over-expression of sima (Drosophila HIF-1α) slows development by 5 days. The 
slower rate of development is also observed in flies raised under mild hypoxia (10% O2). 
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APPENDIX B 
 
FIGURES WITH LEGENDS AND TABLES FOR CHAPTER III 
 
 
Fig. 6. Essenstial domains of the Hairy protein. Hairy, like all HES proteins, contains a 
basic domain (b) for DNA binding, a Helix-Loop-Helix (HLH) domain for dimerization, 
an Orange domain for specificity, a domain for binding the co-repressor Drosophila C-
terminal Binding Protein (dCtBP), and a WRPW motif for binding the potent co-
repressor Groucho.  
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Fig. 7. Putative HREs in the hairy gene region. There are 3 highly conserved putative 
HREs upstream of the promoter region of the hypoxia-response gene hairy. Only 4 of the 
12 sequenced Drosophila genomes are displayed. Putative HRE’s are in red and the 
numbers above represent how many Drosophila species have conservation in these 
regions.  
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TABLE 1: Fold increases in transcript abundance in response to hypoxia in both wild‐type and hairy mutant adult Drosophila.  Wild‐type Fold Change     Transcripts 
3.88 CG18743 Heat-shock-protein-70Ab   
3.81 CG31449 Heat-shock-protein-70Ba   
3.67 CG5834 Hsp70Bbb   
2.96 CG4463 Heat shock protein 23   
2.61 CG10160 Ecdysone-inducible gene L3  
2.49 CG32130     
2.38 CG5436 Heat shock protein 68   
2.38 CG32041 Heat shock gene 67Bb  
2.35 CG12896     
2.25 CG5550     
2.22 CG11825    
2.20 CG4181 Glutathione S transferase D2   
2.06 CG15154 Suppressor of cytokine signaling at 36E  
1.86 CG11765 Peroxiredoxin 2540   
1.83 CG15009 Ecdysone-inducible gene L2   
1.83 CG15009 Ecdysone-inducible gene L2   
1.69 CG17725 Phosphoenolpyruvate carboxykinase  
1.68 CG10383     
1.65 CG8846 Thor    
1.63 CG9434 Frost    
1.63 CG41040     
1.60 CG5592     
1.59 CG10578 DnaJ-like-1   
1.58 CG16898     
1.56 CG31769     
1.55 CG18816 Tetraspanin 42Eb   
1.55 CG13517 Odorant-binding protein 59a   
1.52 CG17524 Glutathione S transferase E3  
1.49 CG5953     
1.47 CG13321    
1.47 O49366_1    
1.47 CG6494 hairy     
1.44 CG13868     
1.44 CG30160     
1.43 CG7219     
1.43 CG15678     
1.40 CG11086    
1.40 CG5408 tribbles   
1.40 CG8709     
1.39 CG16978    
1.39 CG11796     
1.38 CG15784     
1.38 CG7224     
1.36 CG17325     
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1.33 CG3884     
1.28 CG15829    
1.28 CG10078 Phosphoribosylamidotransferase 2  
1.25 CG16926     
1.25 CG32106     
1.25 CG18466 Nmdmc   
1.23 CG8330 tomboy40   
1.21 CG13490     
1.19 CR31541     
1.19 CG9127 adenosine 2   
1.19 CG11652     
1.11 CG10073     
1.09 CG15423     
1.09 CG12489 Defense repressor 1   
1.08 Q9LU32_1    
1.08 CG15893    
1.08 CG14207 HSP20-like chaperone 18D3   
1.05 CG12242 Glutathione S transferase D5   
1.05 CG6687    
1.05 CG13713      
1.05 CG32597    
1.04 CG1552]    
1.03 CG31543 HIF prolyl hydroxylase   
1.02 CR31400 Heat shock RNA &ohgr  
1.00 CG18279 Immune induced molecule 10  
1.00 CG7130    
0.99 CG7850 puckered   
0.99 CR31400 Heat shock RNA &ohgr  
0.97 CG32071     
0.97 CG16844 Immune induced molecule 3   
0.97 CG4779 homogentisate 1,2-dioxygenase 
0.96 CG15673     
0.95 CG2789     
0.95 CG4533 lethal (2) essential for life  
0.94 CG5059    
0.92 CG15043     
0.92 CG5164 Glutathione S transferase E1   
0.92 CG10031 Protease inhibitor I2  
0.90 CR32989 U6atac snRNA at 29B  
0.90 CG7554 comm2    
0.89 CG11992 Relish    
0.89 CG3090 Sox box protein 14  
0.88 CG18106 Immune induced molecule 2   
0.87 CG2914 Ets at 21C    
0.87 CG3705 astray    
0.87 CG14935     
0.87 CG4427 cabut    
0.87 CG16713    
0.86 CG15389 eyes shut   
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0.85 CG8913    
0.85 CG32103     
0.85 CG30489 Cyp12d1-p    
0.84 CG13511     
0.84 CG5295     
0.84 CG4067 pugilist    
0.84 CG11967     
0.82 CG12946     
0.81 CG14933 Proteinase inhibitor I1  
0.80 CG1049 CTP:phosphocholine cytidylyltransferase 1  
0.80 CG4472 Imaginal disc growth factor 1   
0.80 CG2471     
0.80 CG31764 virus-induced RNA 1   
0.80 CG8808 Pyruvate dehydrogenase kinase  
0.79 CG6945    
0.78 CG1333 Ero1L    
0.77 CG11992 Relish    
0.77 CG18330 CTP:phosphocholine cytidylyltransferase 2   
0.76 CG17533 Glutathione S transferase E8   
0.75 CG4183 Heat shock protein 26    
0.75 CG17836     
0.75 CG14383     
0.74 CG4312 Metallothionein B    
0.72 CG8954 Smg5    
0.72 CG5748 Heat shock factor   
0.72 CG12643     
0.72 CG1817 Protein tyrosine phosphatase 10D  
0.72 CR32905 snoRNA:Z1    
0.72 CG3989 ade5   
0.72 CG7590 scylla     
0.71 CG3546     
0.71 CG1921 sprouty    
0.71 CG9453 Serine protease inhibitor 4   
0.71 CG4899 Photoreceptor dehydrogenase   
0.71 CG8501     
0.71 CG15509 kayak     
0.71 CG18233     
0.70 CG1924     
0.70 CG4919 Glutamate-cysteine ligase modifier subunit   
0.70 CG3896     
0.69 CG3365 drongo    
0.69 CG10641     
0.69 CG1014 robl62A   
0.68 CG3884     
0.68 CG15745    
0.68 CG7005 Epidermal stripes and patches   
0.68 CG2275 Jun-related antigen   
0.68 CG10660     
0.66 CG5571    
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0.65 CG1882     
0.65 CG8127 Ecdysone-induced protein 75B   
0.64 CG18317     
0.64 CG1583    
0.63 CG12437 raw    
0.63 CG10962     
0.63 CG10360 refractory to sigma P    
0.63 CG12065     
0.63 CG10045 Glutathione S transferase D1   
0.62 CG31957     
0.62 CG13510    
0.62 CG1630 Inositol 1,4,5-triphosphate kinase 2  
0.62 CG5399     
0.61 CG10245 Cyp6a20    
0.61 CG15658     
0.61 CG1921 sprouty    
0.60 CG10600     
0.60 CG2928 Rhythmically expressed gene 5   
0.60 CG6761    
0.60 CR32894 snoRNA:U29:54Ec  
0.59 CG13279 Cytochrome b5-related    
0.59 CG13689     
Hairy Mutant Fold Change     Transcripts 
4.47 CG18743 Heat-shock-protein-70Ab    
4.12 CG31449 Heat-shock-protein-70Ba    
4.10 CG5834 Hsp70Bbb     
3.41 CG4463 Heat shock protein 23    
3.41 CG5436 Heat shock protein 68   
3.16 CG32041 Heat shock gene 67Bb    
2.66 CG32130      
2.66 CG4181 Glutathione S transferase D2   
2.55 CG10160 Ecdysone-inducible gene L3   
2.12 CG5550      
2.06 CG11825      
2.05 CG15154 Suppressor of cytokine signaling at 36E   
1.94 CG9434 Frost      
1.88 CG12896      
1.86 CG11765 Peroxiredoxin 2540   
1.83 CG15678     
1.78 CG17325      
1.73 CG16978      
1.72 CG8846 Thor     
1.69 CR32905 snoRNA:Z1     
1.67 CG10078 Phosphoribosylamidotransferase 2  
1.64 CG15009 Ecdysone-inducible gene L2    
1.63 CG10578 DnaJ-like-1    
1.61 CG17524 Glutathione S transferase E3    
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1.61 CG11086      
1.60 CG14027 Turandot M     
1.51 CG15784      
1.51 CG5953      
1.48 CG15423     
1.47 CG17725 Phosphoenolpyruvate carboxykinase   
1.47 CG10383      
1.45 CG13321      
1.44 CG15009 Ecdysone-inducible gene L2   
1.43 CR31400 Heat shock RNA &ohgr   
1.41 CG6494 hairy     
1.41 CG17531 Glutathione S transferase E7    
1.37 CG7224      
1.37 CG18466 Nmdmc     
1.36 CG13868     
1.36 CG14207 Heat shock protein Hsp20 HSP20-like chaperone 18D3  
1.33 CG15829 Acyl-coA-binding protein   
1.31 CG5408 tribbles    
1.31 CR32896 snoRNA:snR38:54Eb   
1.29 CG8709  Lipin    
1.26 CR31400 Heat shock RNA &ohgr   
1.26 CG18816 Tetraspanin 42Eb    
1.24 CG7219      
1.24 CG6687      
1.23 CG4533 lethal (2) essential for life   
1.22 CG31769      
1.21 CG3884      
1.19 CG4312 Metallothionein B    
1.17 CG18106 Immune induced molecule 2    
1.16 CR32894 snoRNA:U29:54Ec    
1.16 CG31957      
1.15 CG4183 Heat shock protein 26     
1.15 CG15043     
1.14 CG1552     
1.12 CG15893      
1.12 CG30160     
1.11 CG11652 Diphthamide synthesis     
1.11 CG16926      
1.11 CG2789      
1.10 CG12643      
1.10 CG11796      
1.10 CG11992 Relish     
1.09 CG4608 branchless      
1.09 CG16844 Immune induced molecule 3    
1.08 CG11967      
1.06 CG5592      
1.05 CG15848 Sarcoplasmic calcium-binding protein 1   
1.05 CG13947      
1.04 CG5164 Glutathione S transferase E1     
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1.04 CG9127 adenosine 2     
1.01 CG18330 CTP:phosphocholine cytidylyltransferase 2   
1.00 CG2914 Ets at 21C      
1.00 CG6945      
0.98 CG31764 virus-induced RNA 1    
0.98 CG9568      
0.98 CG8330 tomboy40    
0.97 CG33192 Metallothionein D     
0.96 CG16713 Protease inhibitor I2   
0.96 CG18108 Immune induced molecule 1    
0.96 CR31541      
0.94 CG1367 Cecropin A2    
0.94 CG12489 Defense repressor 1    
0.93 CG18001 Ribosomal protein L38     
0.93 CG4067 pugilist     
0.93 CG3090 Sox box protein 14    
0.93 CG5346      
0.93 CG4427 cabut     
0.92 CG31451      
0.92 CG7850 puckered      
0.92 CG12946      
0.92 CG3896      
0.92 CG33486 asparagine synthetase    
0.90 CG4472 Imaginal disc growth factor 1    
0.90 CG15673      
0.89 CR32989 U6atac snRNA at 29B   
0.89 CG10045 Glutathione S transferase D1    
0.88 CG10041 Peptidase S1    
0.88 CG7554 comm2     
0.88 CG16775     
0.87 CG14933 Proteinase inhibitor I1   
0.86 CG4899 Photoreceptor dehydrogenase    
0.85 CG10570      
0.84 CG8764 oxen     
0.84 CG3705 astray     
0.84 CG4618      
0.84 CR32881 snRNA:U5:38ABa    
0.84 CG14801      
0.84 CG31543 HIF prolyl hydroxylase    
0.83 CG18107      
0.83 CG7130      
0.83 CG8095 scab     
0.82 CG32106      
0.81 CG5461 bunched      
0.81 CR32874 snoRNA:U25:30E    
0.80 CG17836      
0.79 CG31811 centaurin gamma 1A     
0.79 CG15068     
0.78 CG3348      
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0.78 CG13057 retinin     
0.78 CG15509 kayak      
0.78 CG2981 Troponin C at 41C    
0.78 CG15065      
0.77 CG8622 Accessory gland-specific peptide 53Ea   
0.77 CG11089      
0.77 CG32952      
0.77 CG4779 homogentisate 1,2-dioxygenase   
0.76 CG17673 Accessory gland peptide 70A    
0.76 CG11992 Relish     
0.76 CG3884      
0.76 CG32767      
0.75 CG10962      
0.75 CG16712  Protease inhibitor I2   
0.75 CG1049 CTP:phosphocholine cytidylyltransferase 1    
0.75 CG8913      
0.75 CR32865     
0.74 CG14935      
0.74 CG30473 Odorant-binding protein 51a    
0.73 CG4241 alternative testis transcripts open reading frame A   
0.73 CG5059      
0.73 CG8808 Pyruvate dehydrogenase kinase   
0.73 CG32529      
0.72 CG10852 Accessory gland peptide 63F    
0.72 CG1361 Andropin     
0.72 CG33495 Ductus ejaculatorius peptide 99B    
0.71 CG2471     
0.71 CG4802      
0.71 CG1921 sprouty    
0.70 CG5571      
0.70 CG5399      
0.70 CG17239 proteolysis  Peptidase S1   
0.69 CG12065      
0.69 CG4986 Male-specific RNA 57Dc     
0.69 CG1882      
0.69 CG12876      
0.69 CG7590 scylla     
0.69 CR32862 small nuclear RNA U1 at 82Eb   
0.69 CG10031 Protease inhibitor I2   
0.68 CG3943 kraken    
0.68 CG32041 Heat shock gene 67Bb    
0.67 CG5295      
0.67 CG2330      
0.67 CG3986 Chitinase 4     
0.67 CG3871 Six4     
0.67 CG10580 fringe     
0.66 CG12845 Tetraspanin 42Ef   
0.66 CG15658      
0.66 CG17533 Glutathione S transferase E8    
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0.65 CG6761      
0.65 CG13116      
0.64 CG3529      
0.64 CG14542      
0.64 CG18317      
0.64 CR32665 RNA on the X 2     
0.64 CG32137      
0.64 CG8369      
0.64 CG7188      
0.64 CG9285 Dipeptidase B     
0.63 CG4898 Tropomyosin 1     
0.63 CG31549     
0.63 CG15547      
0.63 CR32895 snoRNA:U29:54Ed   
0.63 CG7033      
0.62 CG8127 Ecdysone-induced protein 75B    
0.62 CG16836      
0.62 CG3640      
0.62 CG5352 Small ribonucleoprotein particle protein B   
0.62 CG9415 X box binding protein-1    
0.62 CG16704      
0.62 CG7390 Senescence marker protein-30   
0.62 CG18233      
0.61 CG31468      
0.61 CG32103      
0.61 CG1044 daughter of sevenless   
0.61 CR40454 5.8SrRNA:CR40454    
0.61 CG14724 Cytochrome c oxidase subunit Va   
0.60 CG3989 ade5     
0.60 CG10365      
0.60 CG31704 Proteinase inhibitor I1   
0.60 CG1921 sprouty     
0.60 CG6416     
0.59 CG12775 Ribosomal protein L21    
0.59 CG32039      
0.59 CG5958      
0.59 CG15064 Him     
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TABLE 2: Fold increases in transcript abundance in response to hypoxia in both control cells and hairy‐RNAi cells.   Control cell Fold Change       Transcripts 
3.87 CG8846 Thor     
3.52 CG10160 Ecdysone-inducible gene L3    
3.18 CG7224      
2.51 CG4726      
2.46 CG1552      
2.37 CG15009 Ecdysone-inducible gene L2    
2.34 CG15009 Ecdysone-inducible gene L2    
2.33 CG8330 tomboy40    
2.31 CG10746 fledgling of Klp38B    
2.31 CG3348      
2.28 CG5729 Dgp-1    
2.26 CG18743 Heat-shock-protein-70Ab    
2.14 CG31449 Heat-shock-protein-70Ba    
2.05 CG41040     
2.04 CG31543 HIF prolyl hydroxylase    
1.90 CG31299 nocturnin     
1.89 CG5834 Hsp70Bbb    
1.85 CG7331      
1.82 CG2017      
1.81 CG10242     
1.80 CG1882      
1.79 CG1621      
1.74 CG6494 hairy h     
1.73 CG3767 Juvenile hormone-inducible protein 26   
1.71 CG1014 robl62A    
1.71 CG32041 Heat shock gene 67Bb    
1.68 CG32464 l(3)82Fd    
1.66 CR31541     
1.62 CG3050 Cyp6d5 C    
1.53 CG3424     
1.49 CG17299 SNF4/AMP-activated protein kinase   
1.49 CG1435 sarcoplasmic calcium-binding protein CBP   
1.47 CG32369      
1.47 CG10833      
1.45 CG32464 l(3)82Fd     
1.44 CG4351      
1.43 CG4427 cabut    
1.41 CG18135      
1.38 CG5164 Glutathione S transferase E1   
1.37 CG32512      
1.36 CG17278      
1.36 CG10011      
1.35 CG3476      
1.34 CG2789      
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1.34 CG3001 Hexokinase A     
1.33 CG7130      
1.32 CG33254      
1.31 CG4583 ire-1    
1.31 CG4863 Ribosomal protein L3   
1.30 CG3821 Aspartyl-tRNA synthetase    
1.29 CG6608      
1.29 CG3714      
1.29 CG12800 C     
1.27 CG18578 Ugt86Da     
1.26 CG4832 centrosomin    
1.23 CG11050      
1.22 CG31811 centaurin gamma 1A   
1.22 CG15154 Suppressor of cytokine signaling at 36E   
1.20 CG3017 Aminolevulinate synthase    
1.19 CG10802      
1.18 CG16987 Activin Like Protein at 23B    
1.18 CG12358 polyA-binding protein interacting protein 2   
1.16 CG14005      
1.15 CG17534 Glutathione S transferase E9   
1.15 CG7234 Glutamate receptor IIB    
1.14 CG11652      
1.13 CG15784     
1.11 CG5968      
1.11 CG14709      
1.11 CG6428      
1.11 CG2928 Rhythmically expressed gene 5  
1.09 CG11372 galectin     
1.08 CG4840      
1.08 CG4608 branchless     
1.07 CG4909 Plenty of SH3s     
1.07 CG11779      
1.07 CG11143 Inos    
1.06 CG13117      
1.05 CG12534      
1.05 CG17342 Lk6    
1.05 CG33486 asparagine synthetase    
1.03 CG10360 refractory to sigma P    
1.03 CG5748 Heat shock factor Hsf    
1.03 CG5789      
1.02 CG13624      
1.02 CG10990      
1.02 CG7841      
1.02 CG12317 JhI-21    
1.02 CG17836      
1.01 CG11086      
1.01 CG3825      
1.01 CG7239      
1.01 CG3061 C     
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1.01 CG18317     
1.00 CG33131 SCAP    
0.99 CG14478      
0.99 CG32233      
0.98 CG7737      
0.98 CG1135      
0.97 CG30022      
0.96 CG40100      
0.96 CG30023 sprite     
0.96 CG6815 belphegor     
0.95 CG7717 Mekk1     
0.94 CG1333 Ero1L    
0.94 CG10660      
0.94 CG17724     
0.92 CG7044      
0.92 CG3395 Ribosomal protein S9    
0.92 CG32217 Su(Tpl)     
0.92 CG13517 Odorant-binding protein 59a    
0.92 CG12389 Farnesyl pyrophosphate synthase   
0.92 CG10315 eIF2B-&dgr    
0.91 CG5517 Insulin degrading metalloproteinase  
0.90 CG4944 ciboulot     
0.90 CG6778 Glycyl-tRNA synthetase   
0.90 CG3168      
0.89 CG3458 Topoisomerase 3&bgr   
0.89 CG8198 lethal (1)     
0.89 CG2791      
0.88 CG7235      
0.87 CG7761 parcas     
0.87 CG2803 Troponin C-akin-1   
0.87 CG17533 Glutathione S transferase E8   
0.86 CG1921 sprouty     
0.85 CG9821     
0.85 CG17531 Glutathione S transferase E7    
0.85 CG7590 scylla    
0.85 CG33267      
0.84 CG32103      
0.83 CG7664 cropped    
0.83 CG12425     
0.83 CG4183 Heat shock protein 26    
0.82 CG33123      
0.80 CG33005      
0.80 CG15675     
0.80 CG5247 Inverted repeat-binding protein   
0.80 CG9773     
0.80 CG6115      
0.79 CG7668     
0.79 CG11188      
0.79 CG5010      
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0.78 CG32529     
0.78 CG32742 lethal (1)    
0.78 CG33075 Tyler     
0.78 CG8531      
0.78 CG8913      
0.78 CG6721 GTPase-activating protein 1    
0.78 CG8233      
0.77 CG7954 steamer duck     
0.77 CG1620      
0.77 CG12223 Dorsal switch protein 1    
0.77 CG8251 Phosphoglucose isomerase    
0.77 CG3845 lethal (2)     
0.77 CG9066      
0.77 CG7565      
0.76 CG3782 mitochondrial ribosomal protein L28   
0.76 CG6843      
0.76 CG5874      
0.76 CG10497 Syndecan     
0.76 CG3090 Sox box protein 14    
0.76 CG5165 Phosphogluconate mutase    
0.76 CG10321      
0.76 CG2865      
0.75 CG33162 Signal recognition particle receptor &bgr  
0.75 CG5535      
0.75 CG8443      
0.75 CG4311 HMG Coenzyme A synthase    
0.75 CG6155 Roe1     
0.74 CG5654 ypsilon schachtel    
0.74 CG10778      
0.74 CG30035      
0.74 CG3059 NTPase     
0.74 CG3806 eIF2B-&egr    
0.74 CG5820 Gp150     
0.73 CG10383      
0.73 CG1676 cactin     
0.72 CG8026      
0.72 CG13645      
0.72 CG10535      
0.72 CG11560      
0.71 CG5231 Lipoic acid synthase   
0.71 CG9779      
0.70 CG4589      
0.70 CG30437      
0.70 CG1921 sprouty     
0.70 CG11471 Isoleucyl-tRNA synthetase    
0.70 CG7085 lethal (2) s5379     
0.70 CG7602 DNApol-&igr    
0.70 CG8188     
0.69 CG8190 eIF2B-&ggr    
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0.69 CG5151     
0.69 CG7283 Ribosomal protein L10Ab    
0.69 CG8893 Glyceraldehyde 3 phosphate dehydrogenase 2  
0.69 CG5041 Tfb4    
0.69 CG18596      
0.68 CG17064 mars     
0.68 CG6808      
0.68 CG10578 DnaJ-like-1     
0.68 CG7611 WD-40 repeat Lissencephaly type-1-like homology motif  
       
Hairy‐RNAi Fold Change       Transcripts 
4.10 CG31449 Heat-shock-protein-70Ba   
4.07 CG18743 Heat-shock-protein-70Ab   
4.04 CG5834 Hsp70Bbb     
2.92 CG4183 Heat shock protein 26    
1.83 CG32041 Heat shock gene 67Bb    
1.78 CG3348      
1.67 CG8846 Thor     
1.61 CG4463 Heat shock protein 23   
1.58 CG10160 Ecdysone-inducible gene L3    
1.34 CG4726      
1.21 CG2341 Ccp84Ad     
1.09 CR32905 snoRNA:Z1     
1.01 CG7224      
1.01 CG4982      
0.96 CG3395 Ribosomal protein S9    
0.92 CG31617 His1:CG31617     
0.92 CG33486 asparagine synthetase    
0.90 CG40373      
0.82 CG5164 Glutathione S transferase E1   
0.82 CG31299 nocturnin     
0.82 CG40322      
0.80 CG11086 Ribosomal protein L7Ae/L30e/S12e/Gadd45  
0.79 CG7283 Ribosomal protein L10Ab    
0.78 CG7130     
0.77 CG15154 Suppressor of cytokine signaling at 36E   
0.75 CG4114 expanded     
0.74 CG5729 Dgp-1    
0.73 CG14632      
0.73 CG32369      
0.72 CG1882     
0.71 CG11050     
0.69 CG7602 DNApol-&igr    
0.69 CG10578 DnaJ-like-1     
0.67 CR32887 snoRNA:U31:54Ea   
0.67 CG1474 Es2     
0.67 CR32894 snoRNA:U29:54Ec    
0.67 CG4863 Ribosomal protein L3    
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0.66 CG5748 Heat shock factor    
0.65 CG11652      
0.63 CG32143      
0.62 CG8620      
0.60 CG32143      
0.56 CR31614 His-&PSgr    
0.56 CG2791      
0.56 CG5231 Lipoic acid synthase   
0.56 CG7235      
0.54 CR32899 snoRNA:U31:54Ed    
0.51 CG31543 HIF prolyl hydroxylase    
0.51 CG17531 Glutathione S transferase E7    
0.50 CG17534 Glutathione S transferase E9   
0.49 CG17533 Glutathione S transferase E8   
0.49 CG18317      
0.49 CG14005     
0.48 CR32162 snRNA:U12:73B    
0.48 CG12379     
0.48 CG10778     
0.48 CG32491 modifier of mdg4    
0.47 CG9888 Fibrillarin     
0.46 CG33229     
0.46 CG3476     
0.45 CG2986 overgrown hematopoietic organs at 23B  
0.45 CG1621      
0.44 CG13117      
0.44 CG17023 Dead box protein 80   
0.44 CG6746      
0.44 CG10746 fledgling of Klp38B    
0.43 CG5317      
0.43 CG2017      
0.43 CG11802      
0.42 CG9075 Eukaryotic initiation factor 4a eIF-4a   
0.42 CG2116     
0.42 CG5840      
0.42 CG5231 Lipoic acid synthase   
0.41 CG9895      
0.40 CG17167      
0.40 CG3806 eIF2B-&egr    
0.40 CG4195 lethal (3) 73Ah     
0.39 CG17759 G protein &agr    
0.38 CG31811 centaurin gamma 1A    
0.37 CG13136     
0.37 CG10318 NC2&agr    
0.37 CG1890      
0.36 CG3821 Aspartyl-tRNA synthetase   
0.36 CG32510      
0.36 CG17737      
0.35 CG8261 G protein &ggr    
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0.35 CG7603      
0.35 CG33005      
0.35 CG17153      
0.35 CG14096      
0.35 CG8675     
0.34 CG12317 JhI-21    
0.34 CG17299 SNF4/AMP-activated protein kinase gamma subunit  
0.34 CG11188      
0.34 CG41072     
0.33 CG7737      
0.33 CG1584 Origin recognition complex subunit 6   
0.33 CG17765      
0.33 CG33199      
0.33 CG15012     
0.33 CG2803 Troponin C-akin-1   
0.32 CG6401      
0.32 CG17510     
0.32 CG8580 bhringi    
0.32 CG18578 Ugt86Da    
0.32 CG7954 steamer duck     
0.32 CG9089 wurst     
0.32 CG3495 GDP-4-keto-6-deoxy-D-mannose 3,5-epimerase/4-reductase  
0.31 CG10423 Ribosomal protein S27    
0.31 CG8359      
0.31 CG17187     
0.31 CG1721 Phosphoglyceromutase   
0.31 CG32474 dysfusion     
0.31 CG32068      
0.31 CG9066      
0.31 CG1467 Syntaxin 16     
0.30 CG3260 Zinc finger protein RP-8   
0.30 CG8229      
0.30 CG5446 Heat shock factor binding 1 33E4   
0.30 CG3714     
0.29 CG40451      
0.29 CG15009 Ecdysone-inducible gene L2    
0.29 CG4813      
0.29 CG40084      
0.29 CG14066 La related protein   
0.29 CG16969      
0.29 CG12945      
0.28 CG10306      
0.28 CG12278     
0.28 CG4800 Translationally controlled tumor protein  
0.28 CG14715      
0.27 CG1319      
0.27 CG40224      
0.27 CG5268 black pearl     
0.27 CG3017 Aminolevulinate synthase   
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0.27 CG18593 viral IAP-associated factor    
0.27 CG15514      
0.27 CG12795      
0.27 CG12173     
0.27 CG8860      
0.27 CG4214 Syntaxin 5     
0.26 CG13521 roundabout     
0.26 CG15929 lin-52     
0.26 CG3767 Juvenile hormone-inducible protein 26  
0.26 CG2608      
0.26 CG6038      
0.26 CG5224      
0.26 CG5056      
0.26 CG5861      
0.25 CG30415      
0.25 CG7772      
0.25 CG2674 Minute (2) 21AB     
0.25 CG32672 Autophagy-specific gene 8a    
0.25 CG8206      
0.25 CG12295      
0.25 CG4591 Tetraspanin 86D     
0.25 CG5057 Mediator complex subunit 10    
0.25 CG33184 mitochondrial ribosomal protein L53   
0.25 CG13688 Ipk2    
0.24 CG1715 lethal (3) 03670    
0.24 CG11500      
0.24 CG6608      
0.24 CG5629      
0.24 CG1088 Vacuolar H+-ATPase 26kD E subunit   
0.24 CG6155 Roe1    
0.24 CG6335 Histidyl-tRNA synthetase    
0.24 CG17903 Cytochrome c proximal   
0.24 CG10360 refractory to sigma P   
0.24 CR31615 His-&PSgr    
0.24 CG5941     
0.24 CR32957      
0.24 CG31865      
0.23 CG31492     
0.23 CG7885 RNA polymerase II 33kD subunit   
0.23 CG40274      
0.23 CG9836      
0.23 CG18217      
0.23 CG12265      
0.23 CG17166      
0.23 CG33249      
0.23 CG3034 Mediator complex subunit 22   
0.23 CG7713      
0.23 CG11331 Serpin-27A     
0.23 CG6115      
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0.23 CG6151     
0.23 CG9035 Translocon-associated protein &dgr  
0.23 CG15812 piefke     
0.23 CG5134 Mediator complex subunit 9    
0.23 CG5497 mitochondrial ribosomal protein S28   
0.22 CG7850 puckered puc     
0.22 CG8053 Eukaryotic initiation factor 1A eIF-1A   
0.22 CG5994 Negative elongation factor E    
0.22 CG17023 Dead box protein 80   
0.22 CG9669     
0.22 CG31360     
0.22 CG10851 B52     
0.22 CG11984      
0.22 CG8636      
0.22 CG11110      
0.22 CG5395        
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